Armored NK Cell Therapies Gain Global Momentum
The global field of cell and gene therapy is rapidly evolving toward next-generation “armored” immune cell therapies designed to overcome tumor-mediated immunosuppression. A recent example is AstraZeneca’s USD 630 million agreement to secure global rights to a TGF-β–resistant CAR-T therapy, highlighting increasing industrial confidence in strategies that directly address suppressive tumor microenvironments.